Nrf2 signaling pathway: Pivotal roles in inflammation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1863, Issue 2, 2017, Pages 585-597

  Ahmed, Syed Minhaj Uddin ^a   Luo, Lin ^a,b   Namani, Akhileshwar ^a   Wang, Xiu Jun ^a   Tang, Xiuwen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

ARE; Inflammation; Keap1; Nrf2; Oxidative stress; Phytochemical

Indexed keywords

ANTIINFLAMMATORY AGENT; CELL ADHESION MOLECULE; CHEMOKINE; CRYOPYRIN; CYCLOOXYGENASE 2; CYTOKINE; ENZYME; HO 1 ENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MATRIX METALLOPROTEINASE; PLANT MEDICINAL PRODUCT; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; CLINICAL RESEARCH; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; IMMUNOLOGY;

ANIMALS; HUMANS; INFLAMMATION; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; SIGNAL TRANSDUCTION;

EID: 85003904928     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.11.005     Document Type: Review

References (165)

1. [1] Ferrero-Miliani, L., Nielsen, O.H., Andersen, P.S., Girardin, S.E., Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol. 147 (2007), 227–235.
2. [2] Khansari, N., Shakiba, Y., Mahmoudi, M., Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Patents Inflamm. Allergy Drug Discov. 3 (2009), 73–80.
3. [3] Kaulmann, A., Bohn, T., Carotenoids, inflammation, and oxidative stress–implications of cellular signaling pathways and relation to chronic disease prevention. Nutr. Res. 34 (2014), 907–929.
4. [4] Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B., Oxidative Stress, Inflammation, and Cancer: How are They Linked?, Free Radic. Biol. Med., 49. 1603-1616.
5. [5] Kaplan, M.H., STAT signaling in inflammation. JAKSTAT, 2, 2013, e24198.
6. [6] Braun, S., Hanselmann, C., Gassmann, M.G., Keller, U.a.d., Born-Berclaz, C., Chan, K., Kan, Y.W., Werner, S., Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell. Biol. 22 (2002), 5492–5505.
7. [7] Arisawa, T., Tahara, T., Shibata, T., Nagasaka, M., Nakamura, M., Kamiya, Y., Fujita, H., Hasegawa, S., Takagi, T., Wang, F.Y., Hirata, I., Nakano, H., The relationship between Helicobacter pylori infection and promoter polymorphism of the Nrf2 gene in chronic gastritis. Int. J. Mol. Med. 19 (2007), 143–148.
8. [8] Chen, X.L., Dodd, G., Thomas, S., Zhang, X., Wasserman, M.A., Rovin, B.H., Kunsch, C., Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am. J. Physiol. Heart Circ. Physiol. 290 (2006), H1862–H1870.
9. [9] Wang, H., Liu, K., Geng, M., Gao, P., Wu, X., Hai, Y., Li, Y., Luo, L., Hayes, J.D., Wang, X.J., Tang, X., RXRalpha inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer research 73 (2013), 3097–3108.
10. [10] Namani, A., Li, Y., Wang, X.J., Tang, X., Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer. Biochim. Biophys. Acta 1843 (2014), 1875–1885.
11. [11] Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M., Nabeshima, Y., An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236 (1997), 313–322.
12. [12] Plafker, K.S., Nguyen, L., Barneche, M., Mirza, S., Crawford, D., Plafker, S.M., The ubiquitin-conjugating enzyme UbcM2 can regulate the stability and activity of the antioxidant transcription factor Nrf2. J. Biol. Chem. 285 (2010), 23064–23074.
13. [13] Canning, P., Sorrell, F.J., Bullock, A.N., Structural basis of Keap1 interactions with Nrf2. Free Radic. Biol. Med. 88 (2015), 101–107.
14. [14] Wang, X.J., Li, Y., Luo, L., Wang, H., Chi, Z., Xin, A., Li, X., Wu, J., Tang, X., Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radic. Biol. Med. 70 (2014), 68–77.
15. [15] Cullinan, S.B., Gordan, J.D., Jin, J., Harper, J.W., Diehl, J.A., The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 24 (2004), 8477–8486.
16. [16] Kobayashi, A., Kang, M.I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., Yamamoto, M., Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 24 (2004), 7130–7139.
17. [17] Zhang, D.D., Lo, S.C., Cross, J.V., Templeton, D.J., Hannink, M., Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 24 (2004), 10941–10953.
18. [18] Tong, K.I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., Yamamoto, M., Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol. Cell. Biol. 27 (2007), 7511–7521.
19. [19] Hayes, J.D., McMahon, M., Chowdhry, S., Dinkova-Kostova, A.T., Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal. 13 (2010), 1713–1748.
20. [20] Nioi, P., Nguyen, T., Sherratt, P.J., Pickett, C.B., The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol. Cell. Biol. 25 (2005), 10895–10906.
21. [21] Katoh, Y., Itoh, K., Yoshida, E., Miyagishi, M., Fukamizu, A., Yamamoto, M., Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 6 (2001), 857–868.
22. [22] Kim, J.H., Yu, S., Chen, J.D., Kong, A.N., The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains. Oncogene 32 (2013), 514–527.
23. [23] Li, W., Yu, S.W., Kong, A.N., Nrf2 possesses a redox-sensitive nuclear exporting signal in the Neh5 transactivation domain. J. Biol. Chem. 281 (2006), 27251–27263.
24. [24] Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., Hayes, J.D., Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32 (2013), 3765–3781.
25. [25] Rada, P., Rojo, A.I., Chowdhry, S., McMahon, M., Hayes, J.D., Cuadrado, A., SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell. Biol. 31 (2011), 1121–1133.
26. [26] Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.S., Ueno, I., Sakamoto, A., Tong, K.I., Kim, M., Nishito, Y., Iemura, S., Natsume, T., Ueno, T., Kominami, E., Motohashi, H., Tanaka, K., Yamamoto, M., The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat. Cell Biol. 12 (2010), 213–223.
27. [27] Lau, A., Wang, X.J., Zhao, F., Villeneuve, N.F., Wu, T., Jiang, T., Sun, Z., White, E., Zhang, D.D., A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol. Cell. Biol. 30 (2010), 3275–3285.
28. [28] Jain, A., Lamark, T., Sjottem, E., Larsen, K.B., Awuh, J.A., Overvatn, A., McMahon, M., Hayes, J.D., Johansen, T., p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem. 285 (2010), 22576–22591.
29. [29] Copple, I.M., Lister, A., Obeng, A.D., Kitteringham, N.R., Jenkins, R.E., Layfield, R., Foster, B.J., Goldring, C.E., Park, B.K., Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J. Biol. Chem. 285 (2010), 16782–16788.
30. [30] Shah, N.M., Rushworth, S.A., Murray, M.Y., Bowles, K.M., MacEwan, D.J., Understanding the role of NRF2-regulated miRNAs in human malignancies. Oncotarget 4 (2013), 1130–1142.
31. [31] Sangokoya, C., Telen, M.J., Chi, J.T., microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 116 (2010), 4338–4348.
32. [32] Yang, M., Yao, Y., Eades, G., Zhang, Y., Zhou, Q., MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res. Treat. 129 (2011), 983–991.
33. [33] Narasimhan, M., Patel, D., Vedpathak, D., Rathinam, M., Henderson, G., Mahimainathan, L., Identification of novel microRNAs in post-transcriptional control of Nrf2 expression and redox homeostasis in neuronal, SH-SY5Y cells. PLoS One, 7, 2012, e51111.
34. [34] Singh, B., Ronghe, A.M., Chatterjee, A., Bhat, N.K., Bhat, H.K., MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis 34 (2013), 1165–1172.
35. [35] Chi, X., Yao, W., Xia, H., Jin, Y., Li, X., Cai, J., Hei, Z., Elevation of HO-1 expression mitigates intestinal ischemia-reperfusion injury and restores tight junction function in a rat liver transplantation model. Oxidative Med. Cell. Longev., 986075, 2015.
36. [36] Choi, Y.H., The cytoprotective effect of isorhamnetin against oxidative stress is mediated by the upregulation of the Nrf2-dependent HO-1 expression in C2C12 myoblasts through scavenging reactive oxygen species and ERK inactivation. Gen. Physiol. Biophys., 2016.
37. [37] Kuhn, A.M., Tzieply, N., Schmidt, M.V., von Knethen, A., Namgaladze, D., Yamamoto, M., Brune, B., Antioxidant signaling via Nrf2 counteracts lipopolysaccharide-mediated inflammatory responses in foam cell macrophages. Free Radic. Biol. Med. 50 (2011), 1382–1391.
38. [38] Lee, D.S., Jeong, G.S., Arylbenzofuran isolated from Dalbergia odorifera suppresses lipopolysaccharide-induced mouse BV2 microglial cell activation, which protects mouse hippocampal HT22 cells death from neuroinflammation-mediated toxicity. Eur. J. Pharmacol. 728 (2014), 1–8.
39. [39] Nikam, A., Ollivier, A., Rivard, M., Wilson, J.L., Mebarki, K., Martens, T., Dubois-Rande, J.L., Motterlini, R., Foresti, R., Diverse Nrf2 activators coordinated to cobalt carbonyls induce heme oxygenase-1 and release carbon monoxide in vitro and in vivo. J. Med. Chem. 59 (2016), 756–762.
40. [40] Kim, W., Kim, H.U., Lee, H.N., Kim, S.H., Kim, C., Cha, Y.N., Joe, Y., Chung, H.T., Jang, J., Kim, K., Suh, Y.G., Jin, H.O., Lee, J.K., Surh, Y.J., Taurine chloramine stimulates efferocytosis through upregulation of Nrf2-mediated heme oxygenase-1 expression in murine macrophages: possible involvement of carbon monoxide, antioxidants & redox signaling. 23, 2015, 163–177.
41. [41] Wunder, C., Potter, R.F., The heme oxygenase system: its role in liver inflammation. Curr. Drug Targets Cardiovasc. Haematol. Disord. 3 (2003), 199–208.
42. [42] Prestera, T., Talalay, P., Alam, J., Ahn, Y.I., Lee, P.J., Choi, A.M., Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol. Med. 1 (1995), 827–837.
43. [43] Liu, Y., Zhu, B., Wang, X., Luo, L., Li, P., Paty, D.W., Cynader, M.S., Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 139 (2003), 27–35.
44. [44] Sawada, K., Ohnishi, K., Kosaka, T., Chikano, S., Egashira, A., Okui, M., Shintani, S., Wada, M., Nakasho, K., Shimoyama, T., Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy. J. Gastroenterol. 32 (1997), 689–695.
45. [45] Kadl, A., Pontiller, J., Exner, M., Leitinger, N., Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia. Shock 28 (2007), 582–588.
46. [46] Wang, W.W., Smith, D.L., Zucker, S.D., Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology 40 (2004), 424–433.
47. [47] Lanone, S., Bloc, S., Foresti, R., Almolki, A., Taille, C., Callebert, J., Conti, M., Goven, D., Aubier, M., Dureuil, B., El-Benna, J., Motterlini, R., Boczkowski, J., Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J. 19 (2005), 1890–1892.
48. [48] Kawamura, K., Ishikawa, K., Wada, Y., Kimura, S., Matsumoto, H., Kohro, T., Itabe, H., Kodama, T., Maruyama, Y., Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 155–160.
49. [49] Keshavan, P., Deem, T.L., Schwemberger, S.J., Babcock, G.F., Cook-Mills, J.M., Zucker, S.D., Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J. Immunol. 174 (2005), 3709–3718.
50. [50] Kobayashi, E.H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., Yamamoto, M., Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun., 7, 2016, 11624.
51. [51] Khor, T.O., Huang, M.T., Kwon, K.H., Chan, J.Y., Reddy, B.S., Kong, A.N., Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res. 66 (2006), 11580–11584.
52. [52] Osburn, W.O., Karim, B., Dolan, P.M., Liu, G., Yamamoto, M., Huso, D.L., Kensler, T.W., Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int. J. Cancer 121 (2007), 1883–1891.
53. [53] Pareek, T.K., Belkadi, A., Kesavapany, S., Zaremba, A., Loh, S.L., Bai, L., Cohen, M.L., Meyer, C., Liby, K.T., Miller, R.H., Sporn, M.B., Letterio, J.J., Triterpenoid modulation of IL-17 and Nrf-2expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Sci. Rep., 1, 2011, 201.
54. [54] Thimmulappa, R.K., Scollick, C., Traore, K., Yates, M., Trush, M.A., Liby, K.T., Sporn, M.B., Yamamoto, M., Kensler, T.W., Biswal, S., Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem. Biophys. Res. Commun. 351 (2006), 883–889.
55. [55] Levonen, A.L., Inkala, M., Heikura, T., Jauhiainen, S., Jyrkkanen, H.K., Kansanen, E., Maatta, K., Romppanen, E., Turunen, P., Rutanen, J., Yla-Herttuala, S., Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 741–747.
56. [56] Pae, H.O., Oh, G.S., Lee, B.S., Rim, J.S., Kim, Y.M., Chung, H.T., 3-Hydroxyanthranilic acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cells. Atherosclerosis 187 (2006), 274–284.
57. [57] Yang, L., Froio, R.M., Sciuto, T.E., Dvorak, A.M., Alon, R., Luscinskas, F.W., ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 106 (2005), 584–592.
58. [58] Banning, A., Brigelius-Flohe, R., NF-kappaB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression. Antioxid. Redox Signal. 7 (2005), 889–899.
59. [59] Soares, M.P., Seldon, M.P., Gregoire, I.P., Vassilevskaia, T., Berberat, P.O., Yu, J., Tsui, T.Y., Bach, F.H., Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J. Immunol. 172 (2004), 3553–3563.
60. [60] Thimmulappa, R.K., Lee, H., Rangasamy, T., Reddy, S.P., Yamamoto, M., Kensler, T.W., Biswal, S., Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Invest. 116 (2006), 984–995.
61. [61] Chen, X.L., Varner, S.E., Rao, A.S., Grey, J.Y., Thomas, S., Cook, C.K., Wasserman, M.A., Medford, R.M., Jaiswal, A.K., Kunsch, C., Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism. J. Biol. Chem. 278 (2003), 703–711.
62. [62] Lee, S.H., Sohn, D.H., Jin, X.Y., Kim, S.W., Choi, S.C., Seo, G.S., 2’,4’,6’-tris(methoxymethoxy) chalcone protects against trinitrobenzene sulfonic acid-induced colitis and blocks tumor necrosis factor-alpha-induced intestinal epithelial inflammation via heme oxygenase 1-dependent and independent pathways. Biochem. Pharmacol. 74 (2007), 870–880.
63. [63] Yang, P.M., Wu, Z.Z., Zhang, Y.Q., Wung, B.S., Lycopene inhibits ICAM-1 expression and NF-kappaB activation by Nrf2-regulated cell redox state in human retinal pigment epithelial cells. Life Sci., 2016.
64. [64] Kim, B.C., Jeon, W.K., Hong, H.Y., Jeon, K.B., Hahn, J.H., Kim, Y.M., Numazawa, S., Yosida, T., Park, E.H., Lim, C.J., The anti-inflammatory activity of Phellinus linteus (Berk. & M.A. Curt.) is mediated through the PKCdelta/Nrf2/ARE signaling to up-regulation of heme oxygenase-1. J. Ethnopharmacol. 113 (2007), 240–247.
65. [65] Saw, C.L., Yang, A.Y., Huang, M.T., Liu, Y., Lee, J.H., Khor, T.O., Su, Z.Y., Shu, L., Lu, Y., Conney, A.H., Kong, A.N., Nrf2 null enhances UVB-induced skin inflammation and extracellular matrix damages. Cell Biosci., 4, 2014, 39.
66. [66] Gan, F.F., Ling, H., Ang, X., Reddy, S.A., Lee, S.S., Yang, H., Tan, S.H., Hayes, J.D., Chui, W.K., Chew, E.H., A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-kappaB and Nrf2-Keap1 signaling pathways. Toxicol. Appl. Pharmacol. 272 (2013), 852–862.
67. [67] Benedict, A.L., Mountney, A., Hurtado, A., Bryan, K.E., Schnaar, R.L., Dinkova-Kostova, A.T., Talalay, P., Neuroprotective effects of sulforaphane after contusive spinal cord injury. J. Neurotrauma 29 (2012), 2576–2586.
68. [68] Lin, W., Wu, R.T., Wu, T., Khor, T.O., Wang, H., Kong, A.N., Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem. Pharmacol. 76 (2008), 967–973.
69. [69] Innamorato, N.G., Rojo, A.I., Garcia-Yague, A.J., Yamamoto, M., de Ceballos, M.L., Cuadrado, A., The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 181 (2008), 680–689.
70. [70] Rojo, A.I., Innamorato, N.G., Martin-Moreno, A.M., De Ceballos, M.L., Yamamoto, M., Cuadrado, A., Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58 (2010), 588–598.
71. [71] Chowdhry, S., Nazmy, M.H., Meakin, P.J., Dinkova-Kostova, A.T., Walsh, S.V., Tsujita, T., Dillon, J.F., Ashford, M.L., Hayes, J.D., Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic. Biol. Med. 48 (2010), 357–371.
72. [72] Kim, S.W., Lee, H.K., Shin, J.H., Lee, J.K., Up-down regulation of HO-1 and iNOS gene expressions by ethyl pyruvate via recruiting p300 to Nrf2 and depriving It from p65. Free Radic. Biol. Med. 65 (2013), 468–476.
73. [73] Ho, F.M., Kang, H.C., Lee, S.T., Chao, Y., Chen, Y.C., Huang, L.J., Lin, W.W., The anti-inflammatory actions of LCY-2-CHO, a carbazole analogue, in vascular smooth muscle cells. Biochem. Pharmacol. 74 (2007), 298–308.
74. [74] Strowig, T., Henao-Mejia, J., Elinav, E., Flavell, R., Inflammasomes in health and disease. Nature 481 (2012), 278–286.
75. [75] Bauernfeind, F.G., Horvath, G., Stutz, A., Alnemri, E.S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B.G., Fitzgerald, K.A., Hornung, V., Latz, E., Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183 (2009), 787–791.
76. [76] Shi, F., Kouadir, M., Yang, Y., NALP3 inflammasome activation in protein misfolding diseases. Life Sci. 135 (2015), 9–14.
77. [77] Kolb, R., Liu, G.H., Janowski, A.M., Sutterwala, F.S., Zhang, W., Inflammasomes in cancer: a double-edged sword. Protein Cell 5 (2014), 12–20.
78. [78] Jo, E.K., Kim, J.K., Shin, D.M., Sasakawa, C., Molecular mechanisms regulating NLRP3 inflammasome activation. Cell. Mol. Immunol. 13 (2016), 148–159.
79. [79] Liu, X., Zhang, X., Ding, Y., Zhou, W., Tao, L., Lu, P., Wang, Y., Hu, R., Nuclear factor E2-related factor-2 negatively regulates NLRP3 inflammasome activity by inhibiting reactive oxygen species-induced NLRP3 priming. Antioxid. Redox Signal., 2016.
80. [80] Liu, X., Zhou, W., Zhang, X., Lu, P., Du, Q., Tao, L., Ding, Y., Wang, Y., Hu, R., Dimethyl fumarate ameliorates dextran sulfate sodium-induced murine experimental colitis by activating Nrf2 and suppressing NLRP3 inflammasome activation. Biochem. Pharmacol. 112 (2016), 37–49.
81. [81] Tsai, P.Y., Ka, S.M., Chang, J.M., Chen, H.C., Shui, H.A., Li, C.Y., Hua, K.F., Chang, W.L., Huang, J.J., Yang, S.S., Chen, A., Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic. Biol. Med. 51 (2011), 744–754.
82. [82] Ka, S.M., Lin, J.C., Lin, T.J., Liu, F.C., Chao, L.K., Ho, C.L., Yeh, L.T., Sytwu, H.K., Hua, K.F., Chen, A., Citral alleviates an accelerated and severe lupus nephritis model by inhibiting the activation signal of NLRP3 inflammasome and enhancing Nrf2 activation. Arthritis Res. Ther., 17, 2015, 331.
83. [83] Liu, X., Wang, T., Cai, L., Qi, J., Zhang, P., Li, Y., Biochanin A protects lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Int. Immunopharmacol. 38 (2016), 324–331.
84. [84] He, L., Peng, X., Zhu, J., Chen, X., Liu, H., Tang, C., Dong, Z., Liu, F., Peng, Y., Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects. Am. J. Nephrol. 40 (2014), 441–450.
85. [85] Zhao, C., Gillette, D.D., Li, X., Zhang, Z., Wen, H., Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation. J. Biol. Chem. 289 (2014), 17020–17029.
86. [86] Perkins, N.D., The Rel/NF-kappa B family: friend and foe. Trends Biochem. Sci. 25 (2000), 434–440.
87. [87] Lee, D.F., Kuo, H.P., Liu, M., Chou, C.K., Xia, W., Du, Y., Shen, J., Chen, C.T., Huo, L., Hsu, M.C., Li, C.W., Ding, Q., Liao, T.L., Lai, C.C., Lin, A.C., Chang, Y.H., Tsai, S.F., Li, L.Y., Hung, M.C., KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol. Cell 36 (2009), 131–140.
88. [88] Brigelius-Flohe, R., Flohe, L., Basic principles and emerging concepts in the redox control of transcription factors. Antioxidants & redox signaling 15 (2011), 2335–2381.
89. [89] Liu, G.H., Qu, J., Shen, X., NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim. Biophys. Acta 1783 (2008), 713–727.
90. [90] Yang, H., Magilnick, N., Ou, X., Lu, S.C., Tumour necrosis factor alpha induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor kappaB and activator protein-1. Biochem. J. 391 (2005), 399–408.
91. [91] Hwang, Y.J., Lee, E.W., Song, J., Kim, H.R., Jun, Y.C., Hwang, K.A., MafK positively regulates NF-kappaB activity by enhancing CBP-mediated p65 acetylation. Sci. Rep., 3, 2013, 3242.
92. [92] Bellezza, I., Tucci, A., Galli, F., Grottelli, S., Inhibition of NF-kappaB nuclear translocation via HO-1 activation underlies alpha-tocopheryl succinate toxicity. J. Nutr. Biochem. 23 (2012), 1583–1591.
93. [93] Cho, H.Y., Imani, F., Miller-DeGraff, L., Walters, D., Melendi, G.A., Yamamoto, M., Polack, F.P., Kleeberger, S.R., Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Am. J. Respir. Crit. Care Med. 179 (2009), 138–150.
94. [94] Jiang, T., Tian, F., Zheng, H., Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-kappaB-mediated inflammatory response. Kidney Int. 85 (2014), 333–343.
95. [95] Karuri, A.R., Huang, Y., Bodreddigari, S., Sutter, C.H., Roebuck, B.D., Kensler, T.W., Sutter, T.R., 3H-1,2-dithiole-3-thione targets nuclear factor kappaB to block expression of inducible nitric-oxide synthase, prevents hypotension, and improves survival in endotoxemic rats. J. Pharmacol. Exp. Ther. 317 (2006), 61–67.
96. [96] Heiss, E., Herhaus, C., Klimo, K., Bartsch, H., Gerhauser, C., Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 276 (2001), 32008–32015.
97. [97] Wakabayashi, N., Slocum, S.L., Skoko, J.J., Shin, S., Kensler, T.W., When NRF2 talks, who's listening?. Antioxid. Redox Signal. 13 (2016), 1649–1663.
98. [98] Ahmad, R., Raina, D., Meyer, C., Kharbanda, S., Kufe, D., Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J. Biol. Chem. 281 (2006), 35764–35769.
99. [99] Sriram, N., Kalayarasan, S., Sudhandiran, G., Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling. Pulm. Pharmacol. Ther. 22 (2009), 221–236.
100. [100] Liu, Y.C., Hsieh, C.W., Wu, C.C., Wung, B.S., Chalcone inhibits the activation of NF-kappaB and STAT3 in endothelial cells via endogenous electrophile. Life Sci. 80 (2007), 1420–1430.
101. [101] Yang, H., Magilnick, N., Lee, C., Kalmaz, D., Ou, X., Chan, J.Y., Lu, S.C., Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1. Mol. Cell. Biol. 25 (2005), 5933–5946.
102. [102] Ishii, Y., Itoh, K., Morishima, Y., Kimura, T., Kiwamoto, T., Iizuka, T., Hegab, A.E., Hosoya, T., Nomura, A., Sakamoto, T., Yamamoto, M., Sekizawa, K., Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J. Immunol. 175 (2005), 6968–6975.
103. [103] Rangasamy, T., Cho, C.Y., Thimmulappa, R.K., Zhen, L., Srisuma, S.S., Kensler, T.W., Yamamoto, M., Petrache, I., Tuder, R.M., Biswal, S., Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 114 (2004), 1248–1259.
104. [104] Rangasamy, T., Guo, J., Mitzner, W.A., Roman, J., Singh, A., Fryer, A.D., Yamamoto, M., Kensler, T.W., Tuder, R.M., Georas, S.N., Biswal, S., Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 202 (2005), 47–59.
105. [105] Itoh, K., Mochizuki, M., Ishii, Y., Ishii, T., Shibata, T., Kawamoto, Y., Kelly, V., Sekizawa, K., Uchida, K., Yamamoto, M., Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol. Cell. Biol. 24 (2004), 36–45.
106. [106] Wang, C.Y., Wang, Z.Y., Xie, J.W., Cai, J.H., Wang, T., Xu, Y., Wang, X., An, L., CD36 upregulation mediated by intranasal LV-NRF2 treatment mitigates hypoxia-induced progression of Alzheimer's-like pathogenesis. Antioxid. Redox Signal. 21 (2016), 2208–2230.
107. [107] Escartin, C., Brouillet, E., The Nrf2 pathway as a potential therapeutic target for Huntington disease A commentary on “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington disease”. Free Radic. Biol. Med. 49 (2016), 144–146.
108. [108] Jin, W., Ni, H., Hou, X., Ming, X., Wang, J., Yuan, B., Zhu, T., Jiang, J., Wang, H., Liang, W., Tert-butylhydroquinone protects the spinal cord against inflammatory response produced by spinal cord injury. Ann. Clin. Lab. Sci. 44 (2016), 151–157.
109. [109] Stachel, I., Geismann, C., Aden, K., Deisinger, F., Rosenstiel, P., Schreiber, S., Sebens, S., Arlt, A., Schafer, H., Modulation of nuclear factor E2-related factor-2 (Nrf2) activation by the stress response gene immediate early response-3 (IER3) in colonic epithelial cells: a novel mechanism of cellular adaption to inflammatory stress. J. Biol. Chem. 289 (2016), 1917–1929.
110. [110] Gu, L., Deng, W.S., Liu, Y., Jiang, C.H., Sun, L.C., Sun, X.F., Xu, Q., Zhou, H., Ellagic acid protects Lipopolysaccharide/D-galactosamine-induced acute hepatic injury in mice. Int. Immunopharmacol. 22 (2016), 341–345.
111. [111] Wruck, C.J., Streetz, K., Pavic, G., Gotz, M.E., Tohidnezhad, M., Brandenburg, L.O., Varoga, D., Eickelberg, O., Herdegen, T., Trautwein, C., Cha, K., Kan, Y.W., Pufe, T., Nrf2 induces interleukin-6 (IL-6) expression via an antioxidant response element within the IL-6 promoter. J. Biol. Chem. 286 (2016), 4493–4499.
112. [112] Morito, N., Yoh, K., Itoh, K., Hirayama, A., Koyama, A., Yamamoto, M., Takahashi, S., Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels. Oncogene 22 (2003), 9275–9281.
113. [113] Reddy, N.M., Kleeberger, S.R., Kensler, T.W., Yamamoto, M., Hassoun, P.M., Reddy, S.P., Disruption of Nrf2 impairs the resolution of hyperoxia-induced acute lung injury and inflammation in mice. J. Immunol. 182 (2009), 7264–7271.
114. [114] Dong, J., Ma, Q., Suppression of basal and carbon nanotube-induced oxidative stress, inflammation and fibrosis in mouse lungs by Nrf2. Nanotoxicology, 2016, 1–11.
115. [115] Cho, H.Y., Reddy, S.P., Yamamoto, M., Kleeberger, S.R., The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J. 18 (2004), 1258–1260.
116. [116] Yang, S.M., Chan, Y.L., Hua, K.F., Chang, J.M., Chen, H.L., Tsai, Y.J., Hsu, Y.J., Chao, L.K., Feng-Ling, Y., Tsai, Y.L., Wu, S.H., Wang, Y.F., Tsai, C.L., Chen, A., Ka, S.M., Osthole improves an accelerated focal segmental glomerulosclerosis model in the early stage by activating the Nrf2 antioxidant pathway and subsequently inhibiting NF-kappaB-mediated COX-2 expression and apoptosis. Free Radic. Biol. Med. 73 (2016), 260–269.
117. [117] Freigang, S., Ampenberger, F., Spohn, G., Heer, S., Shamshiev, A.T., Kisielow, J., Hersberger, M., Yamamoto, M., Bachmann, M.F., Kopf, M., Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur. J. Immunol. 41 (2016), 2040–2051.
118. [118] Xue, W.L., Bai, X., Zhang, L., rhTNFR:Fc increases Nrf2 expression via miR-27a mediation to protect myocardium against sepsis injury. Biochem. Biophys. Res. Commun. 464 (2016), 855–861.
119. [119] Keleku-Lukwete, N., Suzuki, M., Otsuki, A., Tsuchida, K., Katayama, S., Hayashi, M., Naganuma, E., Moriguchi, T., Tanabe, O., Engel, J.D., Imaizumi, M., Yamamoto, M., Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proc. Natl. Acad. Sci. U. S. A. 112 (2016), 12169–12174.
120. [120] Maicas, N., Ferrandiz, M.L., Brines, R., Ibanez, L., Cuadrado, A., Koenders, M.I., van den Berg, W.B., Alcaraz, M.J., Deficiency of Nrf2 accelerates the effector phase of arthritis and aggravates joint disease. Antioxid. Redox Signal. 15 (2016), 889–901.
121. [121] Nagai, N., Thimmulappa, R.K., Cano, M., Fujihara, M., Izumi-Nagai, K., Kong, X., Sporn, M.B., Kensler, T.W., Biswal, S., Handa, J.T., Nrf2 is a critical modulator of the innate immune response in a model of uveitis. Free Radic. Biol. Med. 47 (2009), 300–306.
122. [122] Wei, Y., Gong, J., Yoshida, T., Eberhart, C.G., Xu, Z., Kombairaju, P., Sporn, M.B., Handa, J.T., Duh, E.J., Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radic. Biol. Med. 51 (2016), 216–224.
123. [123] Zheng, L., Gong, B., Hatala, D.A., Kern, T.S., Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest. Ophthalmol. Vis. Sci. 48 (2007), 361–367.
124. [124] Aboonabi, A., Singh, I., Chemopreventive role of anthocyanins in atherosclerosis via activation of Nrf2-ARE as an indicator and modulator of redox. Biomed. Pharmacother. 72 (2016), 30–36.
125. [125] Rose, P., Won, Y.K., Ong, C.N., Whiteman, M., Beta-phenylethyl and 8-methylsulphinyloctyl isothiocyanates, constituents of watercress, suppress LPS induced production of nitric oxide and prostaglandin E2 in RAW 264.7 macrophages. Nitric Oxide 12 (2005), 237–243.
126. [126] Balogun, E., Hoque, M., Gong, P., Killeen, E., Green, C.J., Foresti, R., Alam, J., Motterlini, R., Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 371 (2003), 887–895.
127. [127] Cao, T.H., Jin, S.G., Fei, D.S., Kang, K., Jiang, L., Lian, Z.Y., Pan, S.H., Zhao, M.R., Zhao, M.Y., Artesunate protects against sepsis-induced lung injury via heme oxygenase-1 modulation. Inflammation, 2016.
128. [128] Lv, H., Yu, Z., Zheng, Y., Wang, L., Qin, X., Cheng, G., Ci, X., Isovitexin exerts anti-inflammatory and anti-oxidant activities on lipopolysaccharide-induced acute lung injury by inhibiting MAPK and NF-kappaB and activating HO-1/Nrf2 pathways. Int. J. Biol. Sci. 12 (2016), 72–86.
129. [129] Kim, S., Kim, S.J., Yoon, H.E., Chung, S., Choi, B.S., Park, C.W., Shin, S.J., Fimasartan, a novel angiotensin-receptor blocker, protects against renal inflammation and fibrosis in mice with unilateral ureteral obstruction: the possible role of Nrf2. Int. J. Med. Sci. 12 (2016), 891–904.
130. [130] Lee, S., Choi, S.Y., Choo, Y.Y., Kim, O., Tran, P.T., Dao, C.T., Min, B.S., Lee, J.H., Sappanone A exhibits anti-inflammatory effects via modulation of Nrf2 and NF-kappaB. Int. Immunopharmacol. 28 (2016), 328–336.
131. [131] Tao, S., Rojo de la Vega, M., Quijada, H., Wondrak, G.T., Wang, T., Garcia, J.G., Zhang, D.D., Bixin protects mice against ventilation-induced lung injury in an NRF2-dependent manner. Sci. Rep., 6, 2016, 18760.
132. [132] Boyanapalli, S.S., Paredes-Gonzalez, X., Fuentes, F., Zhang, C., Guo, Y., Pung, D., Saw, C.L., Kong, A.N., Nrf2 knockout attenuates the anti-inflammatory effects of phenethyl isothiocyanate and curcumin. Chem. Res. Toxicol. 27 (2016), 2036–2043.
133. [133] Leonardo, C.C., Dore, S., Dietary flavonoids are neuroprotective through Nrf2-coordinated induction of endogenous cytoprotective proteins. Nutr. Neurosci. 14 (2016), 226–236.
134. [134] Li, J., Sapper, T.N., Mah, E., Rudraiah, S., Schill, K.E., Chitchumroonchokchai, C., Moller, M.V., McDonald, J.D., Rohrer, P.R., Manautou, J.E., Bruno, R.S., Green tea extract provides extensive Nrf2-independent protection against lipid accumulation and NFkappaB pro-inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet. Mol. Nutr. Food Res., 2016.
135. [135] Li, C.Z., Jin, H.H., Sun, H.X., Zhang, Z.Z., Zheng, J.X., Li, S.H., Han, S.H., Eriodictyol attenuates cisplatin-induced kidney injury by inhibiting oxidative stress and inflammation. Eur. J. Pharmacol., 2016.
136. [136] Zhu, G.F., Guo, H.J., Huang, Y., Wu, C.T., Zhang, X.F., Eriodictyol, a plant flavonoid, attenuates LPS-induced acute lung injury through its antioxidative and anti-inflammatory activity. Exp. Ther. Med. 10 (2016), 2259–2266.
137. [137] Mielgo-Ayuso, J., Barrenechea, L., Alcorta, P., Larrarte, E., Margareto, J., Labayen, I., Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial. Br. J. Nutr. 111 (2016), 1263–1271.
138. [138] Cheng-Chung Wei, J., Huang, H.C., Chen, W.J., Huang, C.N., Peng, C.H., Lin, C.L., Epigallocatechin gallate attenuates amyloid beta-induced inflammation and neurotoxicity in EOC 13.31 microglia. Eur. J. Pharmacol. 770 (2016), 16–24.
139. [139] Spiller, G.A., Dewell, A., Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J. Med. Food 6 (2003), 51–56.
140. [140] Ormond, D.R., Shannon, C., Oppenheim, J., Zeman, R., Das, K., Murali, R., Jhanwar-Uniyal, M., Stem cell therapy and curcumin synergistically enhance recovery from spinal cord injury. PLoS One, 9, 2016, e88916.
141. [141] Afshariani, R., Farhadi, P., Ghaffarpasand, F., Roozbeh, J., Effectiveness of topical curcumin for treatment of mastitis in breastfeeding women: a randomized, double-blind, placebo-controlled clinical trial. Oman Med J 29 (2016), 330–334.
142. [142] Egner, P.A., Chen, J.G., Wang, J.B., Wu, Y., Sun, Y., Lu, J.H., Zhu, J., Zhang, Y.H., Chen, Y.S., Friesen, M.D., Jacobson, L.P., Munoz, A., Ng, D., Qian, G.S., Zhu, Y.R., Chen, T.Y., Botting, N.P., Zhang, Q., Fahey, J.W., Talalay, P., Groopman, J.D., Kensler, T.W., Bioavailability of sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China. Cancer Prev. Res. (Phila.) 4 (2016), 384–395.
143. [143] Saw, C.L., Huang, M.T., Liu, Y., Khor, T.O., Conney, A.H., Kong, A.N., Impact of Nrf2 on UVB-induced skin inflammation/photoprotection and photoprotective effect of sulforaphane. Mol. Carcinog. 50 (2016), 479–486.
144. [144] Noah, T.L., Zhang, H., Zhou, H., Glista-Baker, E., Muller, L., Bauer, R.N., Meyer, M., Murphy, P.C., Jones, S., Letang, B., Robinette, C., Jaspers, I., Effect of broccoli sprouts on nasal response to live attenuated influenza virus in smokers: a randomized, double-blind study. PLoS One, 9, 2016, e98671.
145. [145] Mirmiran, P., Bahadoran, Z., Golzarand, M., Zojaji, H., Azizi, F., A comparative study of broccoli sprouts powder and standard triple therapy on cardiovascular risk factors following H.pylori eradication: a randomized clinical trial in patients with type 2 diabetes. J Diabetes Metab Disord, 13, 2016, 64.
146. [146] Saldanha, J.F., Leal Vde, O., Stenvinkel, P., Carraro-Eduardo, J.C., Mafra, D., Resveratrol: why is it a promising therapy for chronic kidney disease patients?. Oxidative Med. Cell. Longev., 963217, 2013.
147. [147] Samsami-Kor, M., Daryani, N.E., Asl, P.R., Hekmatdoost, A., Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch. Med. Res. 46 (2016), 280–285.
148. [148] Gill, A.J., Kolson, D.L., Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit. Rev. Immunol. 33 (2016), 307–359.
149. [149] Wang, Y.Y., Yang, Y.X., Zhe, H., He, Z.X., Zhou, S.F., Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des Devel Ther 8 (2016), 2075–2088.
150. [150] Choi, B.H., Kang, K.S., Kwak, M.K., Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules 19 (2016), 12727–12759.
151. [151] Kappos, L., Giovannoni, G., Gold, R., Phillips, J.T., Arnold, D.L., Hotermans, C., Zhang, A., Viglietta, V., Fox, R.J., Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur. J. Neurol. 22 (2016), 664–671.
152. [152] Gao, B., Doan, A., Hybertson, B.M., The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders. Clin. Pharm. 6 (2016), 19–34.
153. [153] Reisman, S.A., Goldsberry, A.R., Lee, C.Y., O'Grady, M.L., Proksch, J.W., Ward, K.W., Meyer, C.J., Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers. BMC Dermatol., 15, 2016, 10.
154. [154] Heinz, S.A., Henson, D.A., Austin, M.D., Jin, F., Nieman, D.C., Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol. Res. 62 (2016), 237–242.
155. [155] Chava, V.K., Vedula, B.D., Thermo-reversible green tea catechin gel for local application in chronic periodontitis: a 4-week clinical trial. J. Periodontol. 84 (2016), 1290–1296.
156. [156] Sakata, R., Nakamura, T., Torimura, T., Ueno, T., Sata, M., Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study. Int. J. Mol. Med. 32 (2013), 989–994.
157. [157] Solhi, H., Ghahremani, R., Kazemifar, A.M., Hoseini Yazdi, Z., Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial. Caspian J Intern Med 5 (2016), 9–12.
158. [158] Rastegarpanah, M., Malekzadeh, R., Vahedi, H., Mohammadi, M., Elahi, E., Chaharmahali, M., Safarnavadeh, T., Abdollahi, M., A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis. Chin J Integr Med., 2016.
159. [159] Yakoot, M., Salem, A., Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterol., 12, 2016, 32.
160. [160] Bime, C., Wei, C.Y., Holbrook, J., Smith, L.J., Wise, R.A., Association of dietary soy genistein intake with lung function and asthma control: a post-hoc analysis of patients enrolled in a prospective multicentre clinical trial. Prim Care Respir J 21 (2016), 398–404.
161. [161] Wagenlehner, F.M., Schneider, H., Ludwig, M., Schnitker, J., Brahler, E., Weidner, W., A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur. Urol. 56 (2009), 544–551.
162. [162] Iwamura, H., Koie, T., Soma, O., Matsumoto, T., Imai, A., Hatakeyama, S., Yoneyama, T., Hashimoto, Y., Ohyama, C., Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urol., 15, 2016, 120.
163. [163] Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T.W., Wasserman, W.W., Biswal, S., Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38 (2016), 5718–5734.
164. [164] Hayes, J.D., Dinkova-Kostova, A.T., The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39 (2016), 199–218.
165. [165] Papp, D., Lenti, K., Modos, D., Fazekas, D., Dul, Z., Turei, D., Foldvari-Nagy, L., Nussinov, R., Csermely, P., Korcsmaros, T., The NRF2-related interactome and regulome contain multifunctional proteins and fine-tuned autoregulatory loops. FEBS Lett. 586 (2016), 1795–1802.